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INTRODUCTION
The 2019 coronavirus disease (COVID-19), caused by the 
severe acute respiratory distress syndrome coronavirus 2 
(SARS-CoV-2), has infected millions of individuals globally, 
accounting for over a million deaths directly attributable to 
infections. Countless other lives have been altered or shortened 
as a result of the multiple and pervasive indirect effects of the 
pandemic. While much of the focus has been on pulmonary 
infection and managing its more severe complications, it has 
become clear that SARS-CoV-2 can result in severe systemic 
inflammation and involve most organ systems. 
The heart has emerged as a primary site of infection, with 
evidence of direct viral replication and viral cytopathy in cardio-
myocytes, fibroblasts, endothelial cells and cardiac interstitial 
cells.(1,2) It is clear that the cardiovascular system plays key roles 
in determining severity of SARS-CoV-2 disease. First, the cell-
surface receptor mediating viral entry into cells is highly 
expressed in cardiovascular tissue.(3) Second, patients with pre-
existing cardiovascular conditions are at considerably greater 
risk of developing severe disease.(4) Finally, many hospitalised 
COVID-19 patients develop acute myocardial injury, and 
elevated biomarkers of this injury are strong predictors of poor 
outcomes.(5) 
Yet, it is not clear how the three phenomena described above 
are interrelated. For instance, questions abound about whether 
elevation in serum biomarkers is causally linked with either viral 
trophism or with pre-existing cardiovascular disease (CVD). 
There is, however, increasing evidence that there are several 
distinct causes of acute myocardial injury in COVID-19, and 







The 2019 coronavirus pandemic (COVID-19), caused by 
SARS-CoV-2, has affected millions globally and has 
accounted for a multitude of deaths. Cardiovascular 
involvement with myocardial injury is common and is 
associated with severe morbidity and mortality. The 
pathophysiology of acute myocardial injury is complex 
and may include type I and type II myocardial infarction, 
direct damage to the cardiomyocytes, systemic infl am-
mation, myocardial interstitial fi brosis, interferon medi-
ated immune response, exaggerated cytokine response 
by Type 1 and 2 helper T cells, in addition to hypoxia. 
Angiotensin converting enzyme-2 receptors (ACE2-R) 
play a pivotal role in mediating viral entry into cells. 
Disruption of receptor signalling may also be the prin-
cipal mechanism facilitating viral pathogenicity and 
altered ACE2-R biology may be a reason why patients 
with cardiovascular disease are more likely to be 
infected with SARS-CoV-2 and more likely to develop 
severe symptoms. New-onset hypertension, arrhythmia, 
myocarditis, heart failure, cardiomyopathy and coronary 
heart disease are among major cardiovascular disease 
comorbidities and complications seen in severe cases of 
COVID-19. As a surrogate for myocardial injury, mul-
tiple studies have shown increased cardiac biomarkers, 
mainly cardiac troponins I and T, in the infected 
patients – especially those with severe disease. Myo-
carditis is another cause of morbidity among COVID-19 
patients.  SAHeart 2020;17:330-337
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at the same time or during different disease phases.(6) A better 
understanding of which patients are at greatest risk and 
identifying modifiable cause(s) of myocardial injury, may have 
direct practical applications for improved management of 
patients with COVID-19.
The link between coronaviruses and CVD is not new. Middle 
East respiratory syndrome coronavirus (MERS-CoV) and SARS-
CoV have both been linked with acute myocardial injury 
associated with clinical phenotypes of myocarditis, acute heart 
failure, left ventricular (LV) systolic dysfunction, arrhythmia and 
plaque rupture.(7-10) Similarly, there are multiple recent reports 
of SARS-CoV-2 causing new-onset hypertension, arrhythmia, 
heart failure, myocarditis, myocardial infarction (MI) and 
Takotsubo.(11-17) In addition, even in the absence of these clinical 
phenotypes, patients experiencing myocardial injury from 
SARS-CoV-2 have a significantly higher risk of in-hospital mor-
tality.(5,18) Given our rapidly evolving understanding of cardio-
vascular involvement in patients with COVID-19, we thought 
it timely to place into context the growing evidence for the 
epidemiology, disease mechanisms and outcomes of myo-
cardial injury from SARS-CoV-2 infection.
EPIDEMIOLOGICAL CONSIDERATIONS
The clinical presentation of COVID-19-associated myocardial 
involvement varies between geographical locations. Reportedly, 
frequent presentations in South Africa involve chest pain and 
symptoms of heart failure, whereas in the United Kingdom, for 
example, patients mainly present with thrombotic myocardial 
infarction initially. Many South African patients present with 
new-onset heart failure, but LV ejection fraction is often pre-
served. Furthermore, genetic factors may play a role in disease 
severity: Black and Asian ethnicity appears to be associated 
with a more severe disease course, with more than fourfold 
risk of death in these ethnic groups in the United Kingdom.
COVID-19 AND ACUTE MYOCARDIAL INJURY
Following recommendations from the Task Force for the 
Fourth Universal Definition of Myocardial Infarction, the 
term myocardial injury (acute or chronic) applies to any patient 
in whom at least one cardiac troponin (cTn) concentration is 
above the 99th percentile upper reference limit (URL).(19) 
Myocardial injury is considered acute if there is a rise and/or a 
fall of cTn values. Cardiac troponin I (cTnI) and T (cTnT) are 
components of the contractile apparatus of myocardial cells 
and are expressed almost exclusively in the heart. Increases in 
cTnI values have not been reported to occur following injury 
to non-cardiac tissues, whereas cTnT may be elevated fol-
lowing injury to skeletal muscle. Myocardial injury is commonly 
encountered clinically and is associated with an adverse prog-
nosis.(19-21) While myocardial injury is a prerequisite for the 
diagnosis of MI, it is also an independent entity. To establish a 
diagnosis of MI, criteria in addition to abnormal biomarkers are 
required. Non-ischaemic myocardial injury may arise secondary 
to many cardiac conditions such as myocarditis or may be 
associated with non-cardiac conditions such as renal failure or 
pulmonary embolism (Table 1).
Myocardial injury is common in patients with COVID-19. 
Incidence of myocardial injury from COVID-19 is unclear due 
to variations in cTn assays, diagnostic thresholds, populations 
studied and timing of samples in relation to disease onset.(22) 
High-sensitivity cTn assays, particularly in patients with greater 
clinical severity, are likely to yield higher values.(5,18,22,23) Patients 
with myocardial injury should be classified as: (i) chronic myo-
cardial injury, (ii) acute non-ischemic myocardial injury, or 
(iii) acute myocardial infarction (MI);(24) all of which are asso-
ciated with increased mortality.(25)
Acute non-ischaemic myocardial injury, in patients with dynamic 
rising and/or falling cTn concentration without clinical evidence 
of myocardial ischaemia, is probably the predominant mecha-
nism for cTn increases in patients with COVID-19.(24) Despite 
emerging reports of myocarditis in patients with COVID-19, 
cTn increases will not always be due to myocarditis: clinical 
context, pre-test probability, and careful clinical evaluation 
should inform the nature of cTn increases. Acute MI is increased 
in COVID-19 due to increased inflammatory, prothrombotic, 
and procoagulant responses. Data from several COVID-19 
studies confirm that this is also the case for COVID-19.(26,27) 
Conceptually, the risk for type 2 MI is higher because of the 
respiratory failure with hypoxia and haemodynamic distur-
bances that occur in COVID-19 with severe illness. 
Chronic cardiovascular disease and COVID-19
In one of the earliest reports of patients who died from 
COVID-19 in Wuhan, important comorbidities included hyper-
tension (20%), diabetes (15%) and CVD (15%).(15) Chronic 
myocardial injury is reported to be associated with established 
CVD and with disease severity.(12,15,28,29) While the overall case 
fatality rate of COVID-19 reported by the Chinese Centre for 
Disease Control and Prevention is 2.3%, the individual case 
fatality rate of patients with CVD is 10.5% [highest among 
those with any comorbidities, including chronic respiratory 
disease (6.3%), cancer (5.6%), diabetes (7.3%) and hypertension 
(6.0%)].(30)
Acute non-ischaemic myocardial injury and COVID-19
Acute LV dysfunction is not a common sequela of COVID-19.(31) 
SARS-CoV-2 infection is associated with acute elevations in 
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NT-proBNP, cTnI and hs-CRP, which are markers of myo-
cardial injury and inflammation, respectively.(32) In addition, ele-
vated cardiac biomarkers were significantly correlated with 
severe disease and critical illness. Age, male sex, elevated serum 
creatinine, hypertension, and coronary artery disease were 
additional factors contributing to disease severity.(32) Eleva-
tions in hs-cTnI were associated with admission to the inten-
sive care unit (ICU).(18) Similarly, in COVID-19 patients who 
required ICU admission, levels of creatine kinase (CK)-MB and 
hs-cTnI were significantly higher.(28) A Chinese case series of 
187 patients with confirmed cases of COVID-19, reported a 
third to have elevated cTnT levels consistent with myocardial 
injury; this group had higher mortality.(25)
Myocarditis is a specific clinical complication of acute non-
ischaemic myocardial damage and can be diagnosed histolog-
ically following endomyocardial biopsy (EMB), on imaging using 
cardiovascular magnetic resonance (CMR) – Figure 1 – or 
clinically. Viral infection is often noted to be a common cause of 
myocarditis. While fulminant myocarditis has been described 
to be associated with COVID-19, most reported cases in the 
literature report a chronic lymphocyte dominant myocarditis 
following SARS-CoV-2 infection.(1,15,16,30,33-35) In a multicentred 
study of 84 patients with COVID-19, 15.5% had abnormal 
electrocardiograms and elevated cardiac enzymes; however, 
only 5% were clinically diagnosed with myocarditis.(36,37) Finally, 
increased levels of N-terminal pro B-type natriuretic peptide 
and cTnI were reported in 27.5% and 10% of patients, respec-
tively; IL-6 and other inflammatory cytokines were elevated in 
patients who experienced a more severe disease course 
requiring ICU admission, leading the authors to postulate that 
elevated cytokines were due to cytokine storm, attributed as 
the cause of fulminant myocarditis in these patients.(33)
Delayed multisystem infl ammatory syndrome in children
A systemic inflammatory response syndrome with severe acute 
myocardial injury and dysfunction that affects children has been 
reported by several groups.(38-40) Notably, this “Kawasaki-like” 
syndrome has a delayed-onset following COVID-19. When 
ethnic origins were reported, early reports from European 
centres indicated a striking association with sub-Saharan black 
ancestry.(40,41) In these reports, the often-severe systolic impair-
ment appeared rapidly reversible following treatment with 
intravenous immunoglobulins (and/or steroids). Diagnosis of 
COVID-19 was made through detection of SARS-CoV-2 
antibodies in the majority of children (82% of 55 cases),(38,39) 
but PCR testing was positive in only a minority (38% of 63 
cases).(38-40) Of note, co-existence of IgM, IgG and IgA in most 
children, is consistent with isotype switching occurring several 
weeks after initial viral exposure.(39) Mechanisms that underlie 
TABLE I: Aetiologies of myocardial injury.
Myocardial injury related to acute 
myocardial ischaemia
Myocardial injury related to acute 
myocardial ischaemia because of oxygen 
supply/demand imbalance
Other causes of myocardial injury
Atherosclerotic plaque disruption with thrombosis A. Reduced myocardial perfusion
• Coronary artery spasm
• Microvascular dysfunction
• Coronary embolism
• Coronary artery dissection
• Sustained bradyarrhythmia








• Coronary revascularisation procedure
• Cardiac procedure other than revascularisation
• Catheter ablation
• Defi brillator shocks
• Cardiac contusion
B. Increased myocardial oxygen demand
• Sustained tachyarrhythmia
•  Severe hypertension with or without left 
ventricular hypertrophy
B. Systemic conditions
• Sepsis or infectious disease
• Chronic kidney disease
• Stroke, subarachnoid haemorrhage
• Pulmonary embolism, pulmonary hypertension
• Infi ltrative disease
• Chemotherapy
• Critically ill patients
• Strenuous exercise













this delayed presentation are presumed to be immunobio-
logical, and it remains possible that the cardiac involvement in 
some adults may follow similar patterns. 
Acute myocardial infarction and COVID-19
While primary percutaneous coronary intervention (PCI) is the 
preferred reperfusion strategy for patients presenting with 
acute MI, its success depends on rapid achievement of 
procedure completion from symptom onset, ideally within 90 
to 120 minutes.(42) In patients with chest pain syndromes 
presenting for care, the ideal time frame of <120 minutes has 
been altered during the coronavirus pandemic for several 
reasons: delayed or refused transfers for bed capacity, lack of 
early cardiac catheterisation laboratory activation, delays in pre-
paration due to personal protective equipment, and COVID-
19-related misleading clinical presentations.(43) Delays in seeking 
medical care in a small cohort of STEMI patients, with a 
median time of 318 minutes from onset of symptoms to first 
medical contact, was described in Hong Kong, and associated 
with poor outcome.(43) During the pandemic, there have been 
numerous reports of diminished numbers of patients presenting 
with acute coronary syndromes. Analysis from 9 high-volume 
hospitals in the United States reported an estimated 38% 
reduction in cardiac catheterisation laboratory STEMI activa-
tions, similar to the 40% reduction noted in Spain.(44,45) 
PATHOPHYSIOLOGY OF MYOCARDIAL INJURY 
IN COVID-19
Pathophysiological mechanisms underlying myocardial injury 
caused by COVID-19 are manifold, with varying amounts of 
evidence for different theories. Figure 2 summarises the pos-
tulated mechanisms. Human SARS-CoV-2 infection of the 
myocardium is dependent on ACE2 receptors. Disruption of 
ACE-2 leads to cardiomyopathy, LV dysfunction, and heart 
failure.(46) Detrimental ACE2 down-regulation limits cardiopro-
tective effects of angiotensin 1 - 7, leading to increased tumour 
necrosis factor alpha (TNFα) production. In COVID-19, ele-
vated TNFα in patients with underlying CVD was associated 
with poor outcomes, supporting the idea of severe inflamma-
tory response as a possible mediator of cardiomyocyte 
damage.(5) There is increasing evidence of direct viral damage 
to the cardiomyocytes, systemic inflammation, endothelial 
shedding, cytokine-induced myocardial injury, myocardial inter-
stitial fibrosis, interferon mediated immune response, exag-
gerated cytokine response by Type 1 and 2 helper T cells, 
electrolyte imbalances, in addition to coronary plaque desta-
bilisation and hypoxia (Figure 3).(2,25,47-49) Swift development of 
innate immunity is important for early clearance of the virus. 
Delayed innate immunity and subsequent activation of adaptive 
immunity is an important determinant of severe myocardial 









FIGURE 1: Cardiovascular magnetic resonance in a patient with COVID-19 myocarditis.
Patient treated for COVID-19 six weeks prior, with low positive cTn. Referred for CMR for evaluation of cause for persistent shortness of breath 
and palpitations. A: Steady-state free precession cine short axis view; B: Short-Tau inversion recovery imaging showing evidence of myocardial 
oedema with signal intensity ratio of 2 between myocardium and remote skeletal muscle; C: T2 map confirming myocardial oedema (T2 = 53 ms); 
D: T1 map at 1.5 Tesla with elevated T1 time (1019 ms); E: Phase-sensitive inversion recovery (PSIR) horizontal long axis image showing mid-wall 
enhancement in the septum and subepicardial enhancement in the inferolateral wall; F: PSIR basal short-axis image with mid-wall enhancement in 
the septum and subepicardial enhancement in the lateral wall; G: PSIR short-axis image at mid-ventricular level showing more confluent mid-wall 
enhancement; and H, postcontrast T1 map with elevated calculated extracellular volume of 32%.
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Infection with SARS-CoV-2 is characterised by a rapid reduction 
in T lymphocytes (both CD4+ and CD8+) in the peripheral 
blood, which precedes the development of symptoms and 
radiological abnormalities.(50,51) Despite the reduction in lym-
phocytes, there is a frequent activation of adaptive immunity 
characterised by highly proinflammatory CCR6+ Th17 CD4+ 
cells and increased cytotoxic granules in CD8+ T cells (perforin 
positive, granulysin positive and granulysin/perforin double-
positive).(51) In addition, abnormalities in T regulatory cells have 
been reported in cases of severe CVD.(52) CD4+ T cells appear 
to play a central role in host-immune defence against SARS-
CoV-2 infections.(53) In acute respiratory distress syndrome and 
in those with a cytokine storm, increased levels of TNF-α, 
IFN-γ, inducible protein 10, IL-6, and IL-8 are elevated and 
thought to contribute to tissue destruction.(54)
CARDIOVASCULAR MANIFESTATIONS OF 
MYOCARDIAL INJURY
Elevated cTn is frequently observed and reflects myocardial 
injury related to COVID-19. In patients with severe and fatal 
COVID-19, higher levels of cTn (>5xULN) were associated 
with severe respiratory failure, tachycardia, systemic hypox-
aemia, myocardial injury either from direct or indirect viral 
myocarditis, endothelial dysfunction or plaque rupture trig-
gered by COVID-19 with subsequent acute coronary syn-
drome, Takotsubo or progression to multiple organ failure.(55) 
High BNP/NT-proBNP levels, seen in severe disease, correlate 
with right ventricular stress. Elevated D-dimers are associated 
with poor outcome; elevated D-dimers on admission correlated 
with COVID-19 in-hospital mortality.(18,56)
Incidence of myocarditis in COVID-19 is unclear, as the spec-
trum of symptoms varies from mild symptoms such as chest 










Viral replication in 
myocardial tissues
Pneumonia induces ARDS 































































Acute (<1 month) Chronic
336
COVID-19 AND MYOCARDIAL INJURY
pain, dyspnoea and fatigue to severe features like biventricular 
failure, cardiogenic shock, arrhythmia, and sudden cardiac 
death. COVID-19 myocarditis is due to a combination of direct 
cell injury and T-lymphocyte-mediated cytotoxicity augmented 
by the cytokine storm.(33) COVID-19-induced myocarditis may 
mimic an acute coronary syndrome with ST segment ele-
vation.(18)
Commonly reported arrhythmias in COVID-19 are atrial 
fibrillation, supraventricular tachycardia and ventricular tachy-
cardia (VT); these may occur in the setting of myocarditis, MI 
and in critically ill patients with hypoxia and shock.(57) Bradycardia 
has rarely been reported. Other mechanisms for arrhythmias 
include electrolyte disturbance (mainly hypokalemia), and 
cardiotoxic therapies (e.g. chloroquine/hydroxychloroquine 
and azithromycin) that prolong QT interval with potential 
development of polymorphic (VT) and fever, which may 
unmask channelopathies such as Brugada syndrome and long 
QT syndrome.
LV systolic dysfunction, acute heart failure, and cardiogenic 
shock are commonly reported in COVID-19, but incidence of 
heart failure is undetermined, and reported to be 52% of 
deceased patients and 12% in discharged patients.(12) EMB in 
patients with COVID-19 reveals intracardiomyocyte virus 
particles.(2,23)
CONCLUSIONS
SARS-CoV-2 is a global health crisis, with strong predilection 
for cardiovascular involvement and myocardial injury. Patterns 
of injury include chronic myocardial injury, acute non-ischaemic 
myocardial injury and acute (type 1) MI. Mechanisms of cardiac 
damage are numerous and include direct insult to myocytes 
by the virus, cytokine and interferon inflammatory responses, 
myocardial interstitial fibrotic response, and T1 and T2 helper 
cell response. Better diagnostic tools and registry data are 
needed for further characterisation of mechanisms of SARS-
CoV-2-related myocardial injury and to help guide develop-
ment of management strategies. At present, there is no specific 
treatment for COVID-19 myocardial injury.
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